PSA-based population screening for PC is not recommended by many authorities and should be limited to men with increased risks of developing the disease.
PSA is not a disease-specific marker for PC, and new parameters help to increase its specificity:
The F/T PSA ratio used for early PC detection before prostatic biopsy or to justify a second biopsy after a negative result.
The PSA kinetics (PSA velocity and PSADT) used in active surveillance and in follow-up of patients after curative treatment.
Promising newer biomarkers are under investigations, but the high costs may preclude their general use in the near future.
References
1.
2.
Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev. 2001;22:184–204.PubMed
3.
4.
5.
6.
Howarth DJ, Aronson IB, Diamandis EP. Immunohistochemical localization of prostate-specific antigen in benign and malignant breast tissues. Br J Cancer. 1997;75(11):1646–51.CrossRefPubMedCentralPubMed
7.
8.
9.
10.
Lin YH, Jiang YG, Li MC, Luo Y, Wang JS. Effects of prostate manipulation on serum total and free prostate specific antigen, and free-to-total prostate specific antigen ratio. Saudi Med J. 2010;31(9):999–1004.PubMed
11.
Kiran PR. Markedly raised serum prostate specific antigen levels. Prostatic infarction rather than malignancy? Aust Fam Physician. 2001;30(5):458–60.PubMed
< div class='tao-gold-member'>
Only gold members can continue reading. Log In or Register a > to continue